New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
08:53 EDTVRX, SLTMValeant completes tender offer for Solta, Solta to no longer be listed on NASDAQ
Valeant Pharmaceuticals (VRX) announced the expiration of the tender offer by a subsidiary of Valeant Pharmaceuticals to purchase all of the outstanding shares of Solta Medical (SLTM) for a price of $2.92 per share in cash, without interest. As a result of the merger, Solta will become a wholly owned subsidiary of VPI. In the merger, each remaining share of Solta that was not validly tendered in the Offer will be cancelled and converted into the right to receive the same $2.92 per share in cash, without interest, that was paid in the Offer. Following completion of the merger, the common stock of Solta will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market today.
News For VRX;SLTM From The Last 14 Days
Check below for free stories on VRX;SLTM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTVRXPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
07:19 EDTVRXValeant top pick in specialty pharmaceutical space, says Cantor
Subscribe for More Information
April 8, 2014
07:08 EDTVRXDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
April 7, 2014
14:09 EDTVRXSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use